Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 178

1.

Elotuzumab plus lenalidomide and dexamethasone for newly diagnosed multiple myeloma: a randomized, open-label, phase 2 study in Japan.

Kubo K, Hori M, Ohta K, Handa H, Hatake K, Matsumoto M, Hagiwara S, Ohashi K, Nakaseko C, Suzuki K, Ito S, Kinoshita G, Shelat SG, Miyoshi M, Takezako N.

Int J Hematol. 2019 Nov 7. doi: 10.1007/s12185-019-02757-0. [Epub ahead of print]

PMID:
31701481
2.

A Prospective, Longitudinal Observation of the Incidence, Treatment, and Survival of Late Acute and Chronic Graft-versus-Host Disease by National Institutes of Health Criteria in a Japanese Cohort.

Ohwada C, Sakaida E, Igarashi A, Kobayashi T, Doki N, Mori T, Kato J, Koda Y, Kanamori H, Tanaka M, Tachibana T, Fujisawa S, Nakajima Y, Numata A, Toyosaki M, Aoyama Y, Onizuka M, Hagihara M, Koyama S, Kanda Y, Nakasone H, Shimizu H, Kato S, Watanabe R, Shono K, Sakai R, Saito T, Nakaseko C, Okamoto S.

Biol Blood Marrow Transplant. 2019 Sep 16. pii: S1083-8791(19)30627-5. doi: 10.1016/j.bbmt.2019.09.016. [Epub ahead of print]

PMID:
31536824
3.

Suppressive effects of anagrelide on cell cycle progression and the maturation of megakaryocyte progenitor cell lines in human induced pluripotent stem cells.

Takaishi K, Takeuchi M, Tsukamoto S, Takayama N, Oshima M, Kimura K, Isshiki Y, Kayamori K, Hino Y, Oshima-Hasegawa N, Mitsukawa S, Takeda Y, Mimura N, Ohwada C, Iseki T, Nakamura S, Eto K, Iwama A, Yokote K, Nakaseko C, Sakaida E.

Haematologica. 2019 Sep 5. pii: haematol.2018.214841. doi: 10.3324/haematol.2018.214841. [Epub ahead of print]

4.

Remarkable donor-derived T cell lymphocytosis before engraftment of a bone marrow transplant for acute lymphoblastic leukemia.

Nagai Y, Tsukamoto S, Hino Y, Isshiki Y, Yamazaki M, Izumi S, Mishina T, Oshima-Hasegawa N, Mitsukawa S, Takeda Y, Mimura N, Ohwada C, Takeuchi M, Iseki T, Nakaseko C, Sakaida E.

Leuk Lymphoma. 2019 Sep 5:1-4. doi: 10.1080/10428194.2019.1660973. [Epub ahead of print] No abstract available.

PMID:
31486335
5.

[POEMS syndrome: advances in molecular pathophysiology and treatment].

Nakaseko C.

Rinsho Ketsueki. 2019;60(8):979-987. doi: 10.11406/rinketsu.60.979. Japanese.

PMID:
31484899
6.

Detection of MYD88 L265P mutation by next-generation deep sequencing in peripheral blood mononuclear cells of Waldenström's macroglobulinemia and IgM monoclonal gammopathy of undetermined significance.

Nakamura A, Ohwada C, Takeuchi M, Takeda Y, Tsukamoto S, Mimura N, Nagisa OH, Sugita Y, Tanaka H, Wakita H, Aotsuka N, Matsue K, Yokote K, Ohara O, Nakaseko C, Sakaida E.

PLoS One. 2019 Sep 4;14(9):e0221941. doi: 10.1371/journal.pone.0221941. eCollection 2019.

7.

KDM2B in polycomb repressive complex 1.1 functions as a tumor suppressor in the initiation of T-cell leukemogenesis.

Isshiki Y, Nakajima-Takagi Y, Oshima M, Aoyama K, Rizk M, Kurosawa S, Saraya A, Kondo T, Sakaida E, Nakaseko C, Yokote K, Koseki H, Iwama A.

Blood Adv. 2019 Sep 10;3(17):2537-2549. doi: 10.1182/bloodadvances.2018028522.

8.

Myeloid/Lymphoid Neoplasm with PDGFRB Rearrangement with t (5;10) (q33;q22) Harboring a Novel Breakpoint of the CCDC6-PDGFRB Fusion Gene.

Yamazaki M, Nakaseko C, Takeuchi M, Ozawa S, Ishizuka Y, Hatanaka Y, Oshima-Hasegawa N, Muto T, Tsukamoto S, Mitsukawa S, Ohwada C, Takeda Y, Mimura N, Iseki T, Fukazawa M, Sakaida E.

Intern Med. 2019 Jul 22. doi: 10.2169/internalmedicine.3220-19. [Epub ahead of print]

9.

T315I mutation with lymphoblasts in a newly diagnosed patient with chronic-phase chronic myeloid leukemia.

Kimura K, Tsukamoto S, Takaishi K, Isshiki Y, Kayamori K, Hino Y, Ohshima-Hasegawa N, Mitsukawa S, Takeda Y, Mimura N, Takeuchi M, Ohwada C, Iseki T, Nakaseko C, Sakaida E.

Leuk Lymphoma. 2019 Jun;60(6):1591-1594. doi: 10.1080/10428194.2018.1548704. Epub 2019 Jan 16. No abstract available.

PMID:
31161870
10.

Efficacy and safety of oral deferasirox treatment for transfusional iron overload in pure red cell aplasia patients after allogeneic stem cell transplantation.

Shimizu R, Takeuchi M, Sakaida E, Ohwada C, Toyosaki M, Machida S, Onizuka M, Shono K, Onoda M, Saito T, Yano S, Tanaka M, Fujisawa S, Mori T, Usuki K, Takahashi S, Kanamori H, Nakaseko C, Okamoto S.

Ann Hematol. 2019 Jul;98(7):1781-1783. doi: 10.1007/s00277-019-03717-8. Epub 2019 May 22. No abstract available.

PMID:
31119366
11.

JSH practical guidelines for hematological malignancies, 2018: III. Myeloma-2. Related disorders of multiple myeloma.

Iida S, Shimazaki C, Abe M, Nakaseko C.

Int J Hematol. 2019 Jun;109(6):633-640. doi: 10.1007/s12185-019-02640-y. Epub 2019 Apr 8. No abstract available.

PMID:
30963472
12.

Immunomodulator-associated Epstein-Barr virus-positive mucocutaneous ulcer in a patient with refractory Crohn's disease.

Hamanaka S, Nakagawa T, Ota S, Iida M, Ohta Y, Isshiki Y, Kasamatsu S, Ishigami H, Taida T, Okimoto K, Saito K, Maruoka D, Matsumura T, Ohwada C, Takeuchi M, Sakaida E, Arai M, Katsuno T, Nakaseko C, Nakatani Y, Kato N.

Clin J Gastroenterol. 2019 Aug;12(4):330-335. doi: 10.1007/s12328-019-00952-4. Epub 2019 Mar 22.

PMID:
30903514
13.

Efficacy and safety of tyrosine kinase inhibitors for newly diagnosed chronic-phase chronic myeloid leukemia over a 5-year period: results from the Japanese registry obtained by the New TARGET system.

Kizaki M, Takahashi N, Iriyama N, Okamoto S, Ono T, Usui N, Inokuchi K, Nakaseko C, Kurokawa M, Sumi M, Nakamura F, Kawaguchi T, Suzuki R, Yamamoto K, Ohnishi K, Matsumura I, Naoe T; New TARGET investigators.

Int J Hematol. 2019 Apr;109(4):426-439. doi: 10.1007/s12185-019-02613-1. Epub 2019 Feb 14.

PMID:
30762219
14.

Randomized study of imatinib for chronic myeloid leukemia: comparing standard dose escalation with aggressive escalation.

Miyamura K, Ohnishi K, Ohtake S, Usui N, Nakaseko C, Fujita H, Fujisawa S, Sakura T, Okumura H, Iriyama N, Emi N, Fujimaki K, Honda S, Miyazaki Y, Naoe T.

Blood Adv. 2019 Feb 12;3(3):312-319. doi: 10.1182/bloodadvances.2018025981.

15.

Low incidence of thromboembolism in multiple myeloma patients receiving immunomodulatory drugs; a retrospective single-institution analysis.

Takaishi K, Tsukamoto S, Ohwada C, Takeuchi M, Kawasaki Y, Nagai Y, Mishina T, Yamazaki M, Isshiki Y, Kayamori K, Kimura K, Hino Y, Oshima-Hasegawa N, Mitsukawa S, Takeda Y, Mimura N, Iseki T, Nakaseko C, Sakaida E.

J Thromb Thrombolysis. 2019 Jul;48(1):141-148. doi: 10.1007/s11239-019-01809-w.

PMID:
30673940
16.

Genetic and transcriptional landscape of plasma cells in POEMS syndrome.

Nagao Y, Mimura N, Takeda J, Yoshida K, Shiozawa Y, Oshima M, Aoyama K, Saraya A, Koide S, Rizq O, Hasegawa Y, Shiraishi Y, Chiba K, Tanaka H, Nishijima D, Isshiki Y, Kayamori K, Kawajiri-Manako C, Oshima-Hasegawa N, Tsukamoto S, Mitsukawa S, Takeda Y, Ohwada C, Takeuchi M, Iseki T, Misawa S, Miyano S, Ohara O, Yokote K, Sakaida E, Kuwabara S, Sanada M, Iwama A, Ogawa S, Nakaseko C.

Leukemia. 2019 Jul;33(7):1723-1735. doi: 10.1038/s41375-018-0348-x. Epub 2019 Jan 11.

PMID:
30635632
17.

[MALT lymphoma accompanied by elevated serum IgM levels mimicking Waldenström's macroglobulinemia].

Izumi S, Kimura K, Takeda Y, Tsukamoto S, Yamazaki M, Mishina T, Nagai Y, Takaishi K, Nagao Y, Oshima-Hasegawa N, Mitsukawa S, Mimura N, Takeuchi M, Ohwada C, Iseki T, Ota S, Nakaseko C, Sakaida E.

Rinsho Ketsueki. 2018;59(12):2600-2605. doi: 10.11406/rinketsu.59.2600. Japanese.

PMID:
30626796
18.

Unsuppressed serum albumin levels may jeopardize the clinical relevance of the international staging system to patients with light chain myeloma.

Kasamatsu T, Ozaki S, Saitoh T, Konishi J, Sunami K, Itagaki M, Asaoku H, Cho T, Handa H, Hagiwara S, Wakayama T, Negoro A, Takezako N, Harada N, Kuroda Y, Nakaseko C, Miyake T, Inoue N, Hata H, Shimazaki C, Ohno T, Kuroda J, Murayama T, Kobayashi T, Abe M, Ishida T, Nagura E, Shimizu K.

Hematol Oncol. 2018 Dec;36(5):792-800. doi: 10.1002/hon.2559. Epub 2018 Sep 19.

PMID:
30176173
19.

A phase 3b, multicenter, open-label extension study of the long-term safety of anagrelide in Japanese adults with essential thrombocythemia.

Kanakura Y, Shirasugi Y, Yamaguchi H, Koike M, Chou T, Okamoto S, Achenbach H, Wu J, Nakaseko C.

Int J Hematol. 2018 Nov;108(5):491-498. doi: 10.1007/s12185-018-2510-7. Epub 2018 Aug 18.

PMID:
30121892
20.

Clonal immunoglobulin λ light-chain gene rearrangements detected by next generation sequencing in POEMS syndrome.

Kawajiri-Manako C, Mimura N, Fukuyo M, Namba H, Rahmutulla B, Nagao Y, Togasaki E, Shimizu R, Oshima-Hasegawa N, Tsukamoto S, Mitsukawa S, Takeda Y, Ohwada C, Takeuchi M, Iseki T, Misawa S, Yokote K, Tsuiji M, Kuwabara S, Sakaida E, Kaneda A, Nakaseko C.

Am J Hematol. 2018 Sep;93(9):1161-1168. doi: 10.1002/ajh.25213. Epub 2018 Aug 31.

21.

Treatment-free remission after two-year consolidation therapy with nilotinib in patients with chronic myeloid leukemia: STAT2 trial in Japan.

Takahashi N, Nishiwaki K, Nakaseko C, Aotsuka N, Sano K, Ohwada C, Kuroki J, Kimura H, Tokuhira M, Mitani K, Fujikawa K, Iwase O, Ohishi K, Kimura F, Fukuda T, Tanosaki S, Takahashi S, Kameoka Y, Nishikawa H, Wakita H; STAT study group.

Haematologica. 2018 Nov;103(11):1835-1842. doi: 10.3324/haematol.2018.194894. Epub 2018 Jul 5.

22.

Long-term complete remission following tandem autologous stem cell transplantation and consolidative radiotherapy for refractory mediastinal gray-zone lymphoma.

Takaishi K, Muto T, Mimura N, Takiguchi J, Nagao Y, Oshima-Hasegawa N, Tsukamoto S, Takeda Y, Mitsukawa S, Takeuchi M, Ohwada C, Ota S, Iseki T, Nakaseko C, Sakaida E.

Int J Hematol. 2018 Oct;108(4):452-455. doi: 10.1007/s12185-018-2471-x. Epub 2018 May 21.

PMID:
29786758
23.

Switching to nilotinib is associated with deeper molecular responses in chronic myeloid leukemia chronic phase with major molecular responses to imatinib: STAT1 trial in Japan.

Noguchi S, Nakaseko C, Nishiwaki K, Ogasawara H, Ohishi K, Tokuhira M, Noguchi M, Kimura H, Handa H, Mitani K, Miura M, Wakita H, Takahashi N; STAT study group.

Int J Hematol. 2018 Aug;108(2):176-183. doi: 10.1007/s12185-018-2459-6. Epub 2018 Apr 30.

PMID:
29713954
24.

Long-term evaluation of physical improvement and survival of autologous stem cell transplantation in POEMS syndrome.

Ohwada C, Sakaida E, Kawajiri-Manako C, Nagao Y, Oshima-Hasegawa N, Togasaki E, Muto T, Tsukamoto S, Mitsukawa S, Takeda Y, Mimura N, Takeuchi M, Shimizu N, Misawa S, Iseki T, Kuwabara S, Nakaseko C.

Blood. 2018 May 10;131(19):2173-2176. doi: 10.1182/blood-2017-07-795385. Epub 2018 Mar 29. No abstract available.

25.

Efficacy and Long-Term Outcomes of Autologous Stem Cell Transplantation in POEMS Syndrome: A Nationwide Survey in Japan.

Kawajiri-Manako C, Sakaida E, Ohwada C, Miyamoto T, Azuma T, Taguchi J, Mori T, Hasegawa Y, Kondo T, Yujiri T, Yoshimitsu M, Imada K, Kurahashi S, Kahata K, Ichinohe T, Hirokawa M, Atsuta Y, Nakaseko C.

Biol Blood Marrow Transplant. 2018 Jun;24(6):1180-1186. doi: 10.1016/j.bbmt.2018.01.026. Epub 2018 Feb 1.

26.

Long-term efficacy of partial splenic embolization for the treatment of steroid-resistant chronic immune thrombocytopenia.

Togasaki E, Shimizu N, Nagao Y, Kawajiri-Manako C, Shimizu R, Oshima-Hasegawa N, Muto T, Tsukamoto S, Mitsukawa S, Takeda Y, Mimura N, Ohwada C, Takeuchi M, Sakaida E, Iseki T, Yoshitomi H, Ohtsuka M, Miyazaki M, Nakaseko C.

Ann Hematol. 2018 Apr;97(4):655-662. doi: 10.1007/s00277-018-3232-x. Epub 2018 Jan 13.

PMID:
29332223
27.

Successful Treatment of Rapidly Progressive Life-Threatening Esophageal Submucosal Hematoma in a Patient With van der Hoeve Syndrome.

Watanabe Y, Shimizu N, Iwakawa M, Yamaguchi T, Ban N, Kawana H, Saiki A, Sakaida E, Nakaseko C, Matsuura Y, Aotsuka N, Bujo H, Tatsuno I.

J Clin Med Res. 2018 Feb;10(2):154-157. doi: 10.14740/jocmr3270w. Epub 2017 Dec 30.

28.

Underweight status at diagnosis is associated with poorer outcomes in adult patients with acute myeloid leukemia: a retrospective study of JALSG AML 201.

Harada K, Doki N, Hagino T, Miyawaki S, Ohtake S, Kiyoi H, Miyazaki Y, Fujita H, Usui N, Okumura H, Miyamura K, Nakaseko C, Fujieda A, Nagai T, Yamane T, Sakamaki H, Ohnishi K, Naoe T, Ohno R, Ohashi K.

Ann Hematol. 2018 Jan;97(1):73-81. doi: 10.1007/s00277-017-3156-x. Epub 2017 Dec 2.

PMID:
29196987
29.

Nilotinib vs. imatinib in Japanese patients with newly diagnosed chronic myeloid leukemia in chronic phase: long-term follow-up of the Japanese subgroup of the randomized ENESTnd trial.

Nakamae H, Fukuda T, Nakaseko C, Kanda Y, Ohmine K, Ono T, Matsumura I, Matsuda A, Aoki M, Ito K, Shibayama H.

Int J Hematol. 2018 Mar;107(3):327-336. doi: 10.1007/s12185-017-2353-7. Epub 2017 Oct 26.

PMID:
29076005
30.

Dasatinib cessation after deep molecular response exceeding 2 years and natural killer cell transition during dasatinib consolidation.

Kumagai T, Nakaseko C, Nishiwaki K, Yoshida C, Ohashi K, Takezako N, Takano H, Kouzai Y, Murase T, Matsue K, Morita S, Sakamoto J, Wakita H, Sakamaki H, Inokuchi K; Kanto CML and Shimousa Hematology Study Groups.

Cancer Sci. 2018 Jan;109(1):182-192. doi: 10.1111/cas.13430. Epub 2017 Nov 29.

31.

The Efficacy of Reduced-dose Dasatinib as a Subsequent Therapy in Patients with Chronic Myeloid Leukemia in the Chronic Phase: The LD-CML Study of the Kanto CML Study Group.

Iriyama N, Ohashi K, Hashino S, Kimura S, Nakaseko C, Takano H, Hino M, Uchiyama M, Morita S, Sakamoto J, Sakamaki H, Inokuchi K.

Intern Med. 2018 Jan 1;57(1):17-23. doi: 10.2169/internalmedicine.9035-17. Epub 2017 Oct 16.

32.

Syndrome of Inappropriate Antidiuretic Hormone Secretion in a Patient with Mucosa-associated Lymphoid Tissue Lymphoma.

Shimizu N, Tanaka S, Watanabe Y, Tokuyama W, Hiruta N, Ohwada C, Sakaida E, Nakaseko C, Tatsuno I.

Intern Med. 2017 Dec 1;56(23):3225-3229. doi: 10.2169/internalmedicine.9048-17. Epub 2017 Oct 11.

33.

Dual Inhibition of EZH2 and EZH1 Sensitizes PRC2-Dependent Tumors to Proteasome Inhibition.

Rizq O, Mimura N, Oshima M, Saraya A, Koide S, Kato Y, Aoyama K, Nakajima-Takagi Y, Wang C, Chiba T, Ma A, Jin J, Iseki T, Nakaseko C, Iwama A.

Clin Cancer Res. 2017 Aug 15;23(16):4817-4830. doi: 10.1158/1078-0432.CCR-16-2735. Epub 2017 May 10.

34.

Frequent somatic mutations in epigenetic regulators in newly diagnosed chronic myeloid leukemia.

Togasaki E, Takeda J, Yoshida K, Shiozawa Y, Takeuchi M, Oshima M, Saraya A, Iwama A, Yokote K, Sakaida E, Hirase C, Takeshita A, Imai K, Okumura H, Morishita Y, Usui N, Takahashi N, Fujisawa S, Shiraishi Y, Chiba K, Tanaka H, Kiyoi H, Ohnishi K, Ohtake S, Asou N, Kobayashi Y, Miyazaki Y, Miyano S, Ogawa S, Matsumura I, Nakaseko C, Naoe T.

Blood Cancer J. 2017 Apr 28;7(4):e559. doi: 10.1038/bcj.2017.36.

35.

Long-term treatment with bosutinib in a phase 1/2 study in Japanese chronic myeloid leukemia patients resistant/intolerant to prior tyrosine kinase inhibitor treatment.

Takahashi N, Nakaseko C, Kobayashi Y, Miyamura K, Ono C, Koide Y, Fujii Y, Ohnishi K.

Int J Hematol. 2017 Sep;106(3):398-410. doi: 10.1007/s12185-017-2239-8. Epub 2017 Apr 13.

PMID:
28409328
36.

Successful Treatment of Hepatocellular Carcinoma Complicated by Fanconi Anemia.

Takahashi K, Suzuki E, Yokoyama M, Inoue M, Wakamatsu T, Saito T, Kusakabe Y, Ogasawara S, Ooka Y, Tawada A, Nagao Y, Nakaseko C, Chiba T.

Case Rep Gastroenterol. 2017 Jan 27;11(1):29-35. doi: 10.1159/000454710. eCollection 2017 Jan-Apr.

37.

The Successful Treatment of a Cord Blood Transplant Recipient with Varicella Zoster Virus Meningitis, Radiculitis and Myelitis with Foscarnet.

Shimizu R, Ohwada C, Nagao Y, Togasaki E, Kawajiri C, Muto T, Tsukamoto S, Sakai S, Takeda Y, Mimura N, Takeuchi M, Sakaida E, Iseki T, Nakaseko C.

Intern Med. 2017;56(3):353-356. doi: 10.2169/internalmedicine.56.6930. Epub 2017 Feb 1.

38.

Safety, efficacy and pharmacokinetics of humanized anti-CD52 monoclonal antibody alemtuzumab in Japanese patients with relapsed or refractory B-cell chronic lymphocytic leukemia.

Ishizawa K, Fukuhara N, Nakaseko C, Chiba S, Ogura M, Okamoto A, Sunaga Y, Tobinai K.

Jpn J Clin Oncol. 2017 Jan;47(1):54-60. doi: 10.1093/jjco/hyw146. Epub 2016 Oct 7.

PMID:
28122892
39.

Outcome of allogeneic hematopoietic stem cell transplantation in adult patients with acute myeloid leukemia harboring trisomy 8.

Konuma T, Kondo T, Yamashita T, Uchida N, Fukuda T, Ozawa Y, Ohashi K, Ogawa H, Kato C, Takahashi S, Kanamori H, Eto T, Nakaseko C, Kohno A, Ichinohe T, Atsuta Y, Takami A, Yano S; Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation (JSHCT).

Ann Hematol. 2017 Mar;96(3):469-478. doi: 10.1007/s00277-016-2909-2. Epub 2017 Jan 6.

PMID:
28058493
40.

Safety and Efficacy of Granulocyte Colony-Stimulating Factor Monotherapy for Peripheral Blood Stem Cell Collection in POEMS Syndrome.

Muto T, Ohwada C, Takaishi K, Isshiki Y, Nagao Y, Hasegawa N, Kawajiri-Manako C, Togasaki E, Shimizu R, Tsukamoto S, Sakai S, Takeda Y, Mimura N, Takeuchi M, Sakaida E, Misawa S, Shimizu N, Iseki T, Kuwabara S, Nakaseko C.

Biol Blood Marrow Transplant. 2017 Feb;23(2):361-363. doi: 10.1016/j.bbmt.2016.10.024. Epub 2016 Nov 10.

41.

Prognostic impact of serum soluble LR11 in newly diagnosed diffuse large B-cell lymphoma: A multicenter prospective analysis.

Sugita Y, Ohwada C, Kawaguchi T, Muto T, Tsukamoto S, Takeda Y, Mimura N, Takeuchi M, Sakaida E, Shimizu N, Tanaka H, Abe D, Fukazawa M, Sugawara T, Aotsuka N, Nishiwaki K, Shono K, Ebinuma H, Fujimura K, Bujo H, Yokote K, Nakaseko C.

Clin Chim Acta. 2016 Dec 1;463:47-52. doi: 10.1016/j.cca.2016.10.008. Epub 2016 Oct 8.

PMID:
27725222
42.

Possible role of intragenic DNA hypermethylation in gene silencing of the tumor suppressor gene NR4A3 in acute myeloid leukemia.

Shimizu R, Muto T, Aoyama K, Choi K, Takeuchi M, Koide S, Hasegawa N, Isshiki Y, Togasaki E, Kawajiri-Manako C, Nagao Y, Tsukamoto S, Sakai S, Takeda Y, Mimura N, Ohwada C, Sakaida E, Iseki T, Starczynowski DT, Iwama A, Yokote K, Nakaseko C.

Leuk Res. 2016 Nov;50:85-94. doi: 10.1016/j.leukres.2016.09.018. Epub 2016 Sep 26.

43.

Impact of combinatorial dysfunctions of Tet2 and Ezh2 on the epigenome in the pathogenesis of myelodysplastic syndrome.

Hasegawa N, Oshima M, Sashida G, Matsui H, Koide S, Saraya A, Wang C, Muto T, Takane K, Kaneda A, Shimoda K, Nakaseko C, Yokote K, Iwama A.

Leukemia. 2017 Apr;31(4):861-871. doi: 10.1038/leu.2016.268. Epub 2016 Oct 3.

PMID:
27694924
44.

Severe stomatitis and ileocecal perforation developed after all-trans retinoic acid monotherapy in an HLA-B51-positive patient with acute promyelocytic leukemia.

Kimura K, Takeuchi M, Hasegawa N, Togasaki E, Shimizu R, Kawajiri C, Muto T, Tsukamoto S, Takeda Y, Ohwada C, Sakaida E, Sakai S, Mimura N, Ota S, Iseki T, Nakaseko C.

Rinsho Ketsueki. 2016 Jun;57(6):765-70. doi: 10.11406/rinketsu.57.765. Review. Japanese.

PMID:
27384858
45.

[Multiple Myeloma: from Diagnosis to the Up-to-date Treatment. Topics: VII. Hematopoietic Stem Cell Transplantation for Multiple Myeloma].

Nakaseko C.

Nihon Naika Gakkai Zasshi. 2016 Jul;105(7):1246-54. Japanese. No abstract available.

PMID:
30168969
46.

Chronic active Epstein-Barr virus infection with marked pericardial effusion successfully treated with allogeneic peripheral blood stem cell transplantation.

Matsui S, Takeda Y, Isshiki Y, Yamazaki A, Nakao S, Takaishi K, Nagao Y, Hasegawa N, Togasaki E, Shimizu R, Kawajiri C, Sakai S, Mimura N, Takeuchi M, Ohwada C, Sakaida E, Iseki T, Imadome K, Nakaseko C.

Rinsho Ketsueki. 2016 May;57(5):624-9. doi: 10.11406/rinketsu.57.624. Review. Japanese.

PMID:
27263789
47.

Donor cell-derived hematological malignancy: a survey by the Japan Society for Hematopoietic Cell Transplantation.

Kato M, Yamashita T, Suzuki R, Matsumoto K, Nishimori H, Takahashi S, Iwato K, Nakaseko C, Kondo T, Imada K, Kimura F, Ichinohe T, Hashii Y, Kato K, Atsuta Y, Taniguchi S, Fukuda T.

Leukemia. 2016 Aug;30(8):1742-5. doi: 10.1038/leu.2016.23. Epub 2016 Feb 12. No abstract available.

PMID:
26867671
48.

Early-Onset Severe Diffuse Alveolar Hemorrhage after Bortezomib Administration Suggestive of Pulmonary Involvement of Myeloma Cells.

Sugita Y, Ohwada C, Nagao Y, Kawajiri C, Shimizu R, Togasaki E, Yamazaki A, Muto T, Sakai S, Takeda Y, Mimura N, Takeuchi M, Sakaida E, Iseki T, Yokote K, Nakaseko C.

J Clin Exp Hematop. 2015;55(3):163-8. doi: 10.3960/jslrt.55.163. Review.

49.

Successful Allogeneic Stem Cell Transplantation for Severe Aplastic Anemia after Treatment of Lymphoproliferative Disorder Caused by Rabbit Antithymocyte Globulin.

Tsukamoto S, Nagao Y, Yamazaki A, Sugita Y, Muto T, Sakai S, Takeda Y, Mimura N, Takeuchi M, Ohwada C, Sakaida E, Yokote K, Iseki T, Nakaseko C.

Intern Med. 2015;54(24):3197-200. doi: 10.2169/internalmedicine.54.5090. Epub 2015 Dec 15.

50.

Successful treatment of cytomegalovirus enteritis after unrelated allogeneic stem cell transplantation by the infusion of ex vivo-expanded CD4+ lymphocytes derived from the recipient's peripheral blood donor cells.

Muto T, Takeda Y, Tsukamoto S, Sakai S, Mimura N, Ohwada C, Takeuchi M, Sakaida E, Ota S, Iseki T, Shimizu N, Morio T, Nakaseko C.

Transpl Infect Dis. 2016 Feb;18(1):93-7. doi: 10.1111/tid.12487. Epub 2016 Jan 30.

PMID:
26613364

Supplemental Content

Loading ...
Support Center